<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T0001" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1080/21645515.2019.1621149-T0001</object-id>
 <label>Table 1.</label>
 <caption>
  <p>WNV vaccine candidates in clinical testing until today.</p>
 </caption>
 <!--OASIS TABLE HERE-->
 <table frame="hsides" rules="groups">
  <colgroup>
   <col width="1*" align="left"/>
   <col width="1*" align="left"/>
   <col width="1*" align="left"/>
   <col width="1*" align="center"/>
   <col width="1*" align="center"/>
  </colgroup>
  <thead>
   <tr>
    <th align="left">Candidate vaccine</th>
    <th align="center">Type</th>
    <th align="center">Key data to date</th>
    <th align="center">Most advanced clinical stage</th>
    <th align="center">References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Hydrovax-001</td>
    <td align="left">Inactivated using hydrogen peroxide</td>
    <td align="left">Neutralizing antibodies in 50% of individuals after two doses.</td>
    <td align="center">I</td>
    <td align="center">
     <sup>
      <xref rid="CIT0020">20</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td align="left">Inactivated WNV</td>
    <td align="left">Inactivated using formaldehyde</td>
    <td align="left">Neutralizing antibodies after three doses.</td>
    <td align="center">I/II</td>
    <td align="center">
     <sup>
      <xref rid="CIT0021">21</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td align="left">ChimeriVax-WN02</td>
    <td align="left">Recombinant yellow fever vaccine strain expressing the prM/E-fragment of WNV</td>
    <td align="left">Neutralizing antibodies (&gt;90%) in younger and older age groups after one dose</td>
    <td align="center">II</td>
    <td align="center">
     <sup>
      <xref rid="CIT0022">22</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td align="left">rWN/DEN4Δ30</td>
    <td align="left">Recombinant attenuated DENV expressing the prM/E-fragment of WNV</td>
    <td align="left">Neutralizing antibodies in 89% of individuals after two doses.</td>
    <td align="center">I</td>
    <td align="center">
     <sup>
      <xref rid="CIT0023">23</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td align="left">HBV-002</td>
    <td align="left">Recombinant truncated E-protein</td>
    <td align="left">Neutralizing antibodies in all individuals after three doses</td>
    <td align="center">I</td>
    <td align="center">
     <sup>
      <xref rid="CIT0024">24</xref>–
      <xref rid="CIT0025">25</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td align="left">VRC WNV</td>
    <td align="left">DNA plasmid expressing the prM/E fragment</td>
    <td align="left">Neutralizing antibodies (&gt;90%) in younger and older age groups after three doses</td>
    <td align="center">I</td>
    <td align="center">
     <sup>
      <xref rid="CIT0026">26</xref>
     </sup>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
